NCT00103467View on ClinicalTrials.gov

Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 30, 2003

Conditions
Prevention of Anthrax Infection
Interventions
BIOLOGICAL

rPA102 Vaccine

Trial Locations (4)

21205

Dept. of International Health - Johns Hopkins University Bloomberg School of Public Health, Baltimore

30322

Emory University School of Medicine, Atlanta

63104

St. Louis University - SoLutions/SLUtest, St Louis

77030

Baylor College of Medicine, Houston

Sponsors

Lead Sponsor

VaxGen
All Listed Sponsors
lead

VaxGen

INDUSTRY

NCT00103467 - Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine | Biotech Hunter | Biotech Hunter